Population Outcomes and Return on Value With CGMs

Author(s):

Davida Kruger, MSN, APN-BC, BC-ADM ,Jaime Murillo, MD, FACC, FASE

Experts discuss the metrics used to evaluate continuous glucose monitoring (CGM)'s comprehensive return on investment, including both cost savings and quality measure performance, and identify which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, along with how these groups are prioritized for CGM access.

EP: 1.CGM: Redefining Type 2 Diabetes Management

EP: 2.Key Benefits of CGM Technology

EP: 3.CGM's Impact on Clinical Inertia

EP: 4.CGM vs Traditional Monitoring

EP: 5.Understanding CGM Metrics

EP: 6.Health Care System Integration

EP: 7.CGM Coverage and Access

EP: 8.Implementation Barriers

EP: 9.Overcoming Access Challenges

EP: 10.Adoption Strategies

EP: 11.The Metro Nashville Public Schools Initiative

EP: 12.Health Care Quality Impact

Now Viewing

EP: 13.Population Outcomes and Return on Value With CGMs

EP: 14.Long-Term Outcomes Assessment

EP: 15.Closing Perspectives

Video content above is prompted by the following:

What metrics do you use to evaluate CGM's comprehensive return on investment, including both cost savings and quality measure performance?
Which patient populations demonstrate the strongest combined benefits in costs, quality measures, and outcomes, and how do you prioritize these groups for CGM access?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!